EUVIMEDEUVIMED entdecken
Crossref

Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer

Jinping Zhang, Lichen Zhang, Jinli Wang, Hui Tang, Liying Tu, Xin Cao, Linping Wang, Lihua Li, Tao Shen, Yunlian Zou

International Immunopharmacology · 2026

DOI: 10.1016/j.intimp.2026.116453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Jinping Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunmin…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Interleukin-12, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) often progresses asymptomatically, resulting in late-stage diagnosis and limited therapeutic options, thus underscoring the urgent need for more effective treatments. Although chimeric antigen receptor (CAR) T-cell therapy demonstrates promise, its efficacy is frequently hindered by the immunosuppressive tumor microenvironment (TME). Interleukin-12 (IL-12), a potent enhancer of T-cell immunity capable of reprogramming the TME, was leveraged in this study by engineering a single-chain recombinant human IL-12 (rhIL-12) fusion protein (p40/p35) cloned into a piggyBac transposon plasmid under either the elongation factor-1α (EF-1α) promoter (PB-IL-12) for constitutive IL-12 secretion or the NFAT-IL-2 promoter (NFAT-IL-12) for antigen-inducible secretion. These IL-12 constructs were co-transfected with a HER2-specific CAR into human T cells, and puromycin-selected HER2-CAR-T cells were subsequently evaluated for antitumor efficacy in vitro and in vivo. In vitro, PB-IL-12-CAR-T cells exhibited significantly reduced proliferation compared to NFAT-IL-12-CAR-T cells or HER2-CAR-T cells lacking IL-12, with phenotypic analysis revealing constitutive IL-12 secretion drove enrichment of CD4+T cells and CD62L+central memory T cells. Functionally, HER2-CAR-T cytotoxicity and IFN-γ correlated with target-antigen density, whereas IL-12 secretion uniformly enhanced tumor-cell killing across both high- and low-antigen tumors. In vivo, IL-12 secretion augmented HER2-CAR-T antitumor activity, with PB-IL-12-CAR-T cells producing higher and more sustained systemic IL-12 and IFN-γ levels than NFAT-IL-12-CAR-T cells while achieving equivalent tumor control. The antigen-inducible system's regulated IL-12 secretion and preserved proliferative potential position it as a promising therapeutic strategy for refractory GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsErb-b2 Receptor Tyrosine KinasesInterleukin-12Immunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansAnimalsCell Line, TumorFemaleMiceInterferon-gammaTumor MicroenvironmentXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Antitumor activityCellular therapyGastric cancerHER2-CAR-T cellsInterleukin-12piggyBac transposon

Substanzen

Erb-b2 Receptor Tyrosine KinasesInterleukin-12ERBB2 protein, humanReceptors, Chimeric AntigenInterferon-gamma

Autor:innen und Institutionen

  • Department of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, China; Yunnan Province Clinical Research Center for Hematolo…
  • Faculty of Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650504, China.
  • Yunnan Digestive Endoscopy Clinical Medical Center, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, China.
  • Center for Regenerative Medicine, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, China.
  • Department of Medical Oncology, The First People's Hospital of Yunnan Province, Kunming 650032, China.
  • Yunnan Provincial Key Laboratory of Clinical virology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, China.

Förderung

  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China

Zitieren

APA

Zhang, J., Zhang, L., Wang, J., Tang, H., Tu, L., Cao, X., Wang, L., Li, L., Shen, T., & Zou, Y. (2026). Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116453

Vancouver

Zhang J, Zhang L, Wang J, Tang H, Tu L, Cao X, et al. Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116453

BibTeX
@article{Zhang2026,
  author = {Zhang, Jinping and Zhang, Lichen and Wang, Jinli and Tang, Hui and Tu, Liying and Cao, Xin and Wang, Linping and Li, Lihua and Shen, Tao and Zou, Yunlian},
  title = {Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer},
  journal = {International Immunopharmacology},
  year = {2026},
  doi = {10.1016/j.intimp.2026.116453}
}
Kostenlos starten →